Form 4: Teva Pharmaceutical Industries: Chief Accounting Officer Reports Share Transactions
SEC Form 4
Amir Weiss, Chief Accounting Officer of Teva Pharmaceutical Industries, reports transactions involving ordinary shares and restricted share units.
Summary
- Amir Weiss, the Chief Accounting Officer of Teva Pharmaceutical Industries, filed a Form 4 detailing changes in beneficial ownership.
- On March 4, 2025, Weiss acquired 10,676 ordinary shares through the vesting of restricted share units and disposed of 21,034 ordinary shares.
- Additionally, Weiss acquired 5,650 ordinary shares through the vesting of restricted share units and disposed of 5,650 ordinary shares.
- Following these transactions, Weiss directly owns 26,684 ordinary shares and 16,950 restricted share units.
- The restricted share units represent a contingent right to receive one ordinary share or its cash value at settlement, as determined by the Human Resources and Compensation Committee.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to insider trading. It doesn't convey any explicit positive or negative sentiment about the company's performance or prospects.
Industry Context
This filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It doesn't necessarily reflect the company's overall performance or strategy but offers insights into individual executive's perspectives.
Stakeholder Impact
- The filing provides transparency to shareholders regarding the transactions of a key executive.
Key Dates
| Date | Description |
|---|---|
| 03/04/2022 | Restricted share units were granted with vesting schedules. |
| 03/04/2023 | 10,676 restricted share units vested. |
| 03/04/2024 | 10,676 restricted share units vested and additional restricted share units were granted with vesting schedules. |
| 03/04/2025 | Transactions occurred involving ordinary shares and restricted share units; 10,676 and 5,650 restricted share units vested. |
| 03/04/2026 | 5,650 restricted share units will vest. |
| 03/04/2027 | 10,679 and 5,650 restricted share units will vest. |
| 03/04/2028 | 5,650 restricted share units will vest. |
| 03/06/2025 | Date of Form 4 filing. |
Keywords
Form 4, Beneficial Ownership, Teva Pharmaceutical Industries, Amir Weiss, Ordinary Shares, Restricted Share Units, Share Transactions, Chief Accounting Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.